PNC-27 10 mg

PNC-27 is a synthetic chimeric anticancer peptide derived from a functional domain of the p53 tumor suppressor protein combined with a membrane-penetrating peptide sequence. It is studied for its unique ability to selectively target cancer cells by binding to human double minute-2 (HDM-2) proteins expressed on cancer cell membranes.

Research interest in PNC-27 peptide Europe has focused on its capacity to form transmembrane pore structures following HDM-2 binding, leading to rapid cancer cell membrane disruption, lysis, and necrosis. Unlike many conventional anticancer strategies, PNC-27 demonstrates selectivity for malignant cells while exhibiting minimal toxicity toward normal, non-transformed cells. Its mechanism of action is independent of intracellular p53 functionality, making it a valuable research compound for cancers with p53 mutation or loss (Sarafraz-Yazdi et al., 2017 — Cancer Letters).

Unlike traditional anticancer agents that rely on apoptosis or intracellular signaling cascades, PNC-27 exerts its effects through direct physical disruption of cancer cell membranes. This extracellular mechanism allows researchers to investigate tumor cell vulnerability independently of cell-cycle status, DNA repair pathways, or p53 transcriptional activity. Ongoing studies continue to explore its selectivity profile across multiple cancer cell lines (Thundimadathil et al., 2012 — Journal of Amino Acids).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling. COA included with every order. See also: BPC-157, MOTS-c, Epitalon